Literature DB >> 16728648

Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.

C P Zabetian1, H Morino, H Ujike, M Yamamoto, M Oda, H Maruyama, Y Izumi, R Kaji, A Griffith, B C Leis, J W Roberts, D Yearout, A Samii, H Kawakami.   

Abstract

LRRK2 G2019S is the most common known cause of Parkinson disease (PD) in patients of European origin, but little is known about its distribution in other populations. The authors identified two of 586 Japanese patients with PD heterozygous for the mutation who shared a haplotype distinct from that observed in Europeans. This suggests that G2019S originated from separate founders in Europe and Japan and is more widely dispersed than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728648     DOI: 10.1212/01.wnl.0000227732.37801.d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

2.  Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana.

Authors:  Roberto Cilia; Francesca Sironi; Albert Akpalu; Momodou Cham; Fred Stephen Sarfo; Tiziana Brambilla; Alba Bonetti; Marianna Amboni; Stefano Goldwurm; Gianni Pezzoli
Journal:  J Neurol       Date:  2011-08-14       Impact factor: 4.849

3.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

4.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Authors:  Cyrus P Zabetian; Carolyn M Hutter; Dora Yearout; Alexis N Lopez; Stewart A Factor; Alida Griffith; Berta C Leis; Thomas D Bird; John G Nutt; Donald S Higgins; John W Roberts; Denise M Kay; Karen L Edwards; Ali Samii; Haydeh Payami
Journal:  Am J Hum Genet       Date:  2006-08-17       Impact factor: 11.025

5.  A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype.

Authors:  C Pirkevi; S Lesage; C Condroyer; H Tomiyama; N Hattori; S Ertan; A Brice; A N Başak
Journal:  Neurogenetics       Date:  2009-01-27       Impact factor: 2.660

6.  Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.

Authors:  Anat Bar-Shira; Carolyn M Hutter; Nir Giladi; Cyrus P Zabetian; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-03-13       Impact factor: 2.660

Review 7.  Parkinson's disease: Exit toxins, enter genetics.

Authors:  Marie Westerlund; Barry Hoffer; Lars Olson
Journal:  Prog Neurobiol       Date:  2009-11-17       Impact factor: 11.685

8.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.

Authors:  Cyrus P Zabetian; Mitsutoshi Yamamoto; Alexis N Lopez; Hiroshi Ujike; Ignacio F Mata; Yuishin Izumi; Ryuji Kaji; Hirofumi Maruyama; Hiroyuki Morino; Masaya Oda; Carolyn M Hutter; Karen L Edwards; Gerard D Schellenberg; Debby W Tsuang; Dora Yearout; Eric B Larson; Hideshi Kawakami
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

Review 9.  LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.

Authors:  Vincenzo Bonifati
Journal:  Neurochem Res       Date:  2007-04-18       Impact factor: 3.996

10.  Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Authors:  Taku Hatano; Manabu Funayama; Shin-Ichiro Kubo; Ignacio F Mata; Yutaka Oji; Akio Mori; Cyrus P Zabetian; Sarah M Waldherr; Hiroyo Yoshino; Genko Oyama; Yasushi Shimo; Ken-Ichi Fujimoto; Hirokazu Oshima; Yasuto Kunii; Hirooki Yabe; Yoshikuni Mizuno; Nobutaka Hattori
Journal:  Neurobiol Aging       Date:  2014-06-02       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.